| Literature DB >> 33361335 |
Gaylor Boulay1,2, Luisa Cironi3,4, Sara P Garcia1, Shruthi Rengarajan1, Yu-Hang Xing1, Lukuo Lee1, Mary E Awad1, Beverly Naigles1, Sowmya Iyer1, Liliane C Broye3,4, Tugba Keskin3,4, Alexandra Cauderay3,1, Carlo Fusco3,4, Igor Letovanec3, Ivan Chebib1, Petur Gunnalugur Nielsen1, Stéphane Tercier5, Stéphane Cherix6, Tu Nguyen-Ngoc7, Gregory Cote8, Edwin Choy8, Paolo Provero9,10, Mario L Suvà1,2, Miguel N Rivera1,2, Ivan Stamenkovic11,4, Nicolò Riggi12,4.
Abstract
Synovial sarcoma (SyS) is an aggressive mesenchymal malignancy invariably associated with the chromosomal translocation t(X:18; p11:q11), which results in the in-frame fusion of the BAF complex gene SS18 to one of three SSX genes. Fusion of SS18 to SSX generates an aberrant transcriptional regulator, which, in permissive cells, drives tumor development by initiating major chromatin remodeling events that disrupt the balance between BAF-mediated gene activation and polycomb-dependent repression. Here, we developed SyS organoids and performed genome-wide epigenomic profiling of these models and mesenchymal precursors to define SyS-specific chromatin remodeling mechanisms and dependencies. We show that SS18-SSX induces broad BAF domains at its binding sites, which oppose polycomb repressor complex (PRC) 2 activity, while facilitating recruitment of a non-canonical (nc)PRC1 variant. Along with the uncoupling of polycomb complexes, we observed H3K27me3 eviction, H2AK119ub deposition and the establishment of de novo active regulatory elements that drive SyS identity. These alterations are completely reversible upon SS18-SSX depletion and are associated with vulnerability to USP7 loss, a core member of ncPRC1.1. Using the power of primary tumor organoids, our work helps define the mechanisms of epigenetic dysregulation on which SyS cells are dependent.Entities:
Year: 2020 PMID: 33361335 PMCID: PMC7768195 DOI: 10.26508/lsa.202000808
Source DB: PubMed Journal: Life Sci Alliance ISSN: 2575-1077